Dr Janice Knowlden
Research Associate
Publication
2021
2011
- Hutcheson, I. R. et al. 2011. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research 13(2), article number: R29. (10.1186/bcr2848)
- Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5(2), pp. 67-77. (10.1515/HMBCI.2011.009)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2011. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Research 13(5), article number: R93. (10.1186/bcr3018)
2010
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2010. O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. EJC Supplements 8(6), pp. 13-14. (10.1016/j.ejcsup.2010.06.037)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2010. Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. Breast Cancer Research 12(S1), pp. S15. (10.1186/bcr2546)
2008
- Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M. W., Nicholson, R. I. and Hutcheson, I. R. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), pp. 79-91. (10.1007/s10549-007-9763-9)
- Knowlden, J. M. 2008. Role of insulin-like growth factor-type 1 receptor (IGF-IR) signalling in tamoxifen-resistant breast cancer. PhD Thesis, Cardiff University.
2007
2006
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D. and Nicholson, R. I. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13(S1), pp. S45-S51. (10.1677/erc.1.01275)
- Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279)
- Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96(2), pp. 131-146. (10.1007/s10549-005-9070-2)
2005
- Knowlden, J. M., Hutcheson, I. R., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2005. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146(11), pp. 4609-4618. (10.1210/en.2005-0247)
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Knowlden, J. M., Giles, M. G., Barrow, D. and Gee, J. M. W. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12(S1), pp. S29-S36. (10.1677/erc.1.00991)
- Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
2004
- Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11(4), pp. 793-814. (10.1677/erc.1.00799)
- Rushmere, N. K., Knowlden, J. M., Gee, J. M. W., Harper, M. E., Robertson, J. F. R., Morgan, B. P. and Nicholson, R. I. 2004. Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. International Journal of Cancer 108(6), pp. 930-936. (10.1002/ijc.11606)
- Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
- Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker, pp. 249-258.
2003
- Hutcheson, I. R., Knowlden, J. M., Madden, T., Barrow, D., Gee, J. M. W., Wakeling, A. E. and Nicholson, R. I. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81(1), pp. 81-93. (10.1023/A:1025484908380)
- Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), pp. 1032-1044. (10.1210/en.2002-220620)
- Nicholson, R. I., Gee, J. M. W., Knowlden, J. M., McClelland, R. A., Madden, T., Barrow, D. and Hutcheson, I. R. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80(S1), pp. 29-34. (10.1023/A:1025467500433)
- Hutcheson, I. R., Knowlden, J. M., Barrow, D., Gee, J. M. W., Robertson, J. F., Wakeling, A. E. and Nicholson, R. I. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S170. (10.1023/A:1026252325164)
- Gee, J. M. W. and Knowlden, J. M. 2003. ADAM metalloproteases and EGFR signalling [Viewpoint]. Breast Cancer Research 5(5), pp. 223-224. (10.1186/bcr637)
2002
2001
2000
1999
- Seery, L. T., Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Kenny, F. S., Ellis, I. O. and Nicholson, R. I. 1999. [Corrigendum] BRCA1 expression levels predict distant metastasis of sporadic breast cancer (vol 84, pg 258, 1999). International Journal of Cancer 84(5), pp. 544-544. (10.1002/(SICI)1097-0215(19991022)84:5<544::AID-IJC18>3.0.CO;2-9)
- Seery, L. T., Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Kenny, F. S., Ellis, I. O. and Nicholson, R. I. 1999. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. International Journal of Cancer 84(3), pp. 258-262. (10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H)
1998
1997
1996
1995
Articles
- Fakes, L., Hutcheson, I. and Knowlden, J. 2021. The role of the glucocorticoid receptor in anti-hormone resistance in breast cancer. The British Student Doctor Journal 5(1), pp. 18-31. (10.18573/bsdj.184)
- Hutcheson, I. R. et al. 2011. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research 13(2), article number: R29. (10.1186/bcr2848)
- Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5(2), pp. 67-77. (10.1515/HMBCI.2011.009)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2011. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Research 13(5), article number: R93. (10.1186/bcr3018)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2010. O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. EJC Supplements 8(6), pp. 13-14. (10.1016/j.ejcsup.2010.06.037)
- Knowlden, J. M., Gee, J. M. W., Barrow, D., Robertson, J. F., Ellis, I. O., Nicholson, R. I. and Hutcheson, I. R. 2010. Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. Breast Cancer Research 12(S1), pp. S15. (10.1186/bcr2546)
- Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M. W., Nicholson, R. I. and Hutcheson, I. R. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), pp. 79-91. (10.1007/s10549-007-9763-9)
- Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9(4), article number: R50. (10.1186/bcr1754)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D. and Nicholson, R. I. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13(S1), pp. S45-S51. (10.1677/erc.1.01275)
- Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279)
- Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96(2), pp. 131-146. (10.1007/s10549-005-9070-2)
- Knowlden, J. M., Hutcheson, I. R., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2005. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146(11), pp. 4609-4618. (10.1210/en.2005-0247)
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Knowlden, J. M., Giles, M. G., Barrow, D. and Gee, J. M. W. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12(S1), pp. S29-S36. (10.1677/erc.1.00991)
- Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
- Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11(4), pp. 793-814. (10.1677/erc.1.00799)
- Rushmere, N. K., Knowlden, J. M., Gee, J. M. W., Harper, M. E., Robertson, J. F. R., Morgan, B. P. and Nicholson, R. I. 2004. Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. International Journal of Cancer 108(6), pp. 930-936. (10.1002/ijc.11606)
- Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
- Hutcheson, I. R., Knowlden, J. M., Madden, T., Barrow, D., Gee, J. M. W., Wakeling, A. E. and Nicholson, R. I. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81(1), pp. 81-93. (10.1023/A:1025484908380)
- Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), pp. 1032-1044. (10.1210/en.2002-220620)
- Nicholson, R. I., Gee, J. M. W., Knowlden, J. M., McClelland, R. A., Madden, T., Barrow, D. and Hutcheson, I. R. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80(S1), pp. 29-34. (10.1023/A:1025467500433)
- Hutcheson, I. R., Knowlden, J. M., Barrow, D., Gee, J. M. W., Robertson, J. F., Wakeling, A. E. and Nicholson, R. I. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S170. (10.1023/A:1026252325164)
- Gee, J. M. W. and Knowlden, J. M. 2003. ADAM metalloproteases and EGFR signalling [Viewpoint]. Breast Cancer Research 5(5), pp. 223-224. (10.1186/bcr637)
- Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38(S7), pp. S59. (10.1016/S0959-8049(02)80835-8)
- Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7(S), pp. 3766S.
- Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8(3), pp. 175-182. (10.1677/erc.0.0080175)
- McClelland, R. A. et al. 2001. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142(7), pp. 2776-2788. (10.1210/en.142.7.2776)
- Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Ellis, I. O. and Nicholson, R. I. 2000. A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. International Journal of Cancer 89(2), pp. 209-212. (10.1002/(SICI)1097-0215(20000320)89:2<209::AID-IJC17>3.0.CO;2-6)
- Seery, L. T., Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Kenny, F. S., Ellis, I. O. and Nicholson, R. I. 1999. [Corrigendum] BRCA1 expression levels predict distant metastasis of sporadic breast cancer (vol 84, pg 258, 1999). International Journal of Cancer 84(5), pp. 544-544. (10.1002/(SICI)1097-0215(19991022)84:5<544::AID-IJC18>3.0.CO;2-9)
- Seery, L. T., Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Kenny, F. S., Ellis, I. O. and Nicholson, R. I. 1999. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. International Journal of Cancer 84(3), pp. 258-262. (10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H)
- Knowlden, J. M. et al. 1998. C-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17(15), pp. 1949-1957.
- Knowlden, J. M. et al. 1997. Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clinical Cancer Research 3(11), pp. 2165-2172.
- Manning, D. L. et al. 1995. Differential expression of estrogen-regulated genes in breast-cancer. Acta Oncologica 34(5), pp. 641-646.
Book sections
- Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker, pp. 249-258.
- Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al. eds. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963. New York: The New York Academy of Sciences, pp. 104-115., (10.1111/j.1749-6632.2002.tb04101.x)
- Nicholson, R. I. et al. 1996. Pure antiestrogens - The most important advance in the endocrine therapy of breast cancer since 1896?. In: Castagnetta, L., Nenci, I. and Bradlow, H. L. eds. Basis for Cancer Management. Annals of the New York Academy of Sciences Vol. 784. New York: New York Academy of Sciences, pp. 325-335., (10.1111/j.1749-6632.1996.tb16247.x)
Thesis